New depression drug GM-2505 enters Mid-Stage trial
Symptom relief
Recruiting now
This study tests an experimental drug called GM-2505 in people with major depressive disorder. Participants receive two doses of the drug two weeks apart. The study has three parts: one for people not on antidepressants, one for those partially responding to current treatment, an…
Phase: PHASE2 • Sponsor: Gilgamesh Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC